In this article, the authors showed the combination effect of PAC-1 with vemurafenib, osimertinib, and ceritinib against BRAFV600E melanoma, EGFRT790M lung cancer, and EML4-ALK lung cancer and in all cancer cell-lines, and the acquisition of resistance was substantially delayed or eliminated. This evidence concerns the gene ALK and lung cancer.